JP2023538325A5 - - Google Patents

Info

Publication number
JP2023538325A5
JP2023538325A5 JP2023509838A JP2023509838A JP2023538325A5 JP 2023538325 A5 JP2023538325 A5 JP 2023538325A5 JP 2023509838 A JP2023509838 A JP 2023509838A JP 2023509838 A JP2023509838 A JP 2023509838A JP 2023538325 A5 JP2023538325 A5 JP 2023538325A5
Authority
JP
Japan
Prior art keywords
aryl
alkyl
heterocyclyl
cycloalkyl
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538325A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/045448 external-priority patent/WO2022035904A1/en
Publication of JP2023538325A publication Critical patent/JP2023538325A/ja
Publication of JP2023538325A5 publication Critical patent/JP2023538325A5/ja
Pending legal-status Critical Current

Links

JP2023509838A 2020-08-11 2021-08-10 プロテアソームエンハンサー及びその使用 Pending JP2023538325A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063064262P 2020-08-11 2020-08-11
US63/064,262 2020-08-11
PCT/US2021/045448 WO2022035904A1 (en) 2020-08-11 2021-08-10 Proteasome enhancers and uses thereof

Publications (2)

Publication Number Publication Date
JP2023538325A JP2023538325A (ja) 2023-09-07
JP2023538325A5 true JP2023538325A5 (cg-RX-API-DMAC7.html) 2024-08-20

Family

ID=83103414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509838A Pending JP2023538325A (ja) 2020-08-11 2021-08-10 プロテアソームエンハンサー及びその使用

Country Status (7)

Country Link
US (1) US20240043394A1 (cg-RX-API-DMAC7.html)
EP (1) EP4196464A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023538325A (cg-RX-API-DMAC7.html)
AU (1) AU2021324687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3191312A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023001761A (cg-RX-API-DMAC7.html)
WO (1) WO2022035904A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025124250A (ja) * 2024-02-14 2025-08-26 株式会社ジェイテクト 転舵制御装置

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469772A (en) * 1973-06-21 1977-04-06 Boots Co Ltd Fungicidal imidazole derivatives
DE4430091A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
SI0999826T1 (en) * 1997-07-29 2004-12-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
EP1268477B1 (en) * 2000-03-15 2010-04-21 Sanofi-Aventis Deutschland GmbH Substituted beta-carbolines with ikb-kinase inhibiting activity
MX2013000391A (es) * 2010-07-12 2013-03-08 Hoffmann La Roche 1-hidroxiimino-3-fenil-propanos.
JP6490464B2 (ja) * 2014-03-26 2019-03-27 三井化学株式会社 遷移金属化合物、オレフィン重合用触媒およびオレフィン系重合体の製造方法
CN107021938A (zh) * 2017-05-26 2017-08-08 陕西科技大学 一种1‑吩噻嗪基‑3‑芳基‑3‑氰基亚甲基‑1‑丙酮及其制备方法
CN107216323A (zh) * 2017-05-26 2017-09-29 陕西科技大学 一种1‑吩噻嗪基‑3‑芳基‑3‑(2,4,6‑嘧啶三酮基)‑1‑丙酮及其制备方法
WO2019084157A1 (en) * 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
WO2019156991A1 (en) * 2018-02-06 2019-08-15 The Regents Of The University Of California Methods of inhibiting formation of alpha synuclein aggregates

Similar Documents

Publication Publication Date Title
CA2927656C (en) Mek inhibitors and methods of their use
JP2021534124A5 (cg-RX-API-DMAC7.html)
MX2010005717A (es) Derivados de isoxazolo-piridina.
JP2009519243A5 (cg-RX-API-DMAC7.html)
JP2011219498A5 (cg-RX-API-DMAC7.html)
EA201400105A1 (ru) Применение 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты и содержащие их фармацевтические композиции
CA2526884A1 (en) P2x7 receptor antagonists and their use
JP2006526617A5 (cg-RX-API-DMAC7.html)
CA2632194A1 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
JP4607107B2 (ja) シクロプロピル基置換されたオキサゾリジノン抗生物質およびこれらの誘導体
JP2016516043A5 (cg-RX-API-DMAC7.html)
JP2009542716A5 (cg-RX-API-DMAC7.html)
CA2449441A1 (en) 3-fluoro-pyrrolidines as antidiabetic agents
PE20081530A1 (es) Nuevos compuestos 617
JP2011513305A5 (cg-RX-API-DMAC7.html)
JP2009534468A5 (cg-RX-API-DMAC7.html)
JP2020535165A5 (cg-RX-API-DMAC7.html)
JP2022512736A5 (cg-RX-API-DMAC7.html)
NZ599254A (en) Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals
SI3102573T1 (en) SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7
JP2023538326A5 (cg-RX-API-DMAC7.html)
CN115667236A (zh) 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用
JP2011517697A5 (cg-RX-API-DMAC7.html)
JP2012523457A5 (cg-RX-API-DMAC7.html)
JP2024540318A5 (cg-RX-API-DMAC7.html)